The overexpression of OPH in some prostate cancers suggests that chemotherapeutic prodrugs esters modeled after known ester substrates of OPH (i.e., α-naphthyl N-acetyl-alaninate) have potential in treating some prostate cancers. The gene discussed is APEH; the disease is prostate carcinoma.